Heart Attacks: TiGenix advances its cardiac stem-cell therapy

24/09/2015 - 3 minutes

Belgian TiGenix NV released the phase I results of their cardiac stem-cell therapy at the Congress of the European Society of Cardiology (ESC) in London earlier this month. In July, TiGenix acquired the smaller biotech CoreTherapix with the AlloCSC-01 pipeline. This stem-cell therapy is for regeneration of heart muscle following a heart attack, and is currently undergoing its phase II trial ‘CAREMI’.

TigenixTiGenix NV, from Leuven (Belgium) recently bought out Madrid-based CoreTherapix, a former subsidiary of Spanish biotech Genetrix for a contractual total of €267M. This is a hefty sum for a small biotech only founded in 2008, for sure. However, it is the excitement surrounding Coretherapix’s cardiac stem cell therapy AlloCSC-01 which has sparked a euromillion rush.

AlloCSC-01 is designed as a reparative tool to treat patients who have experienced an acute myocardial infarction (AMI) in order to reduce ischemic damage. Phase I results have been overwhelmingly positive, with AlloCSC-01 demonstrating a comprehensive safety profile (announced at the ESC). Since over 1.5 million AMIs occur annually across the US and EU,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!